Filling the need for trusted information on national health issues

Amid heightened public concern, the cost of prescription drugs is the focus of renewed attention by the Trump administration and lawmakers in Congress and state capitals. Proposed actions range from sweeping health care system changes to targeted initiatives that could affect Medicare, Medicaid and private insurance. See KFF’s research, analysis and public opinion data, as well as Kaiser Health News’ journalism, related to prescription drugs and their costs.

  • Your Selections:

Refine Results

date

Topics

Content Type

Tags

Health News Index – March/April 2002

Health News Index March/April, 2002 The March/April edition of the Kaiser Family Foundation/Harvard School of Public Health Health News Index includes questions about major health stories covered in the news, including the recent coverage of mammogram efficacy, the Institute of Medicine report on racial disparities in the health care system,…

National ADAP Monitoring Project: Annual Report, April 2002

This report, the sixth in an annual series, provides an overview of the status of state-administered AIDS Drug Assistance Programs (ADAPs) and documents how these programs are responding to the changing fiscal, clinical and epidemiological dynamics of HIV/AIDS. ADAPs, authorized under Title II of the Ryan White Comprehensive AIDS Resources…

2001 Retiree Health and Prescription Drug Coverage Survey-6020

2001 Retiree Health and Prescription Drug Coverage SurveyThis survey, released by the Kaiser Family Foundation, The Commonwealth Fund, and HRET, profiles retiree health coverage for Medicare-age (65+) retirees, including the amount retirees pay for coverage compared to active workers, cost-sharing for prescription drugs, and eligibility requirements for retiree benefits. The…

State Variation in Medicaid Pharmacy Benefit Use Among Dual-Eligible Beneficiaries

This study examines Medicaid pharmacy benefit use and spending among beneficiaries dually eligible for Medicare and Medicaid in 10 states by analyzing 1995 enrollment and claims data from a new 12-state database. The study finds that dual-eligibles are relatively high users of the Medicaid pharmacy benefit, with substantial variation in…

The President’s Fiscal Year 2003 Budget:  An Overview of Health Programs

The President's Fiscal Year 2003 Budget: An Overview of Health ProgramsA new chartbook describes the government's overall budget situation and examines the health policies and programs proposed in the President's latest budget.Chartbook View a webcast of A Capitol Hill briefing on budgets and health care

Prescription Drug Discount Card Programs: Implications for Medicare Beneficiaries

This testimony was delivered by Tricia Neuman, a vice president of the Kaiser Family Foundation, at a Senate Finance Committee hearing on the Bush Administration's Proposals for Medicare Modernization. The statement, which draws upon a report prepared for the Foundation by Health Policy Alternatives, Inc., provides an overview of existing…

Prescription Drug Discount Cards: Current Programs and Issues

As policymakers consider a range of approaches to providing prescription drug coverage to the Medicare population in today s tight budgetary environment, one proposal that has been put forth by the Bush Administration is that of a Medicare-endorsed prescription drug discount card program. This report describes the range of existing…

Health News Index January/February 2002

Health News Index January/February, 2002 The January/February 2002 edition of the Kaiser Family Foundation/ Harvard School of Public Health Health News Index includes questions about major health stories covered in the news, including the public s knowledge of the ongoing anthrax investigation and prescription drug discount cards. The Health News…

States Strive to Limit Medicaid Expenditures for Prescribed Drugs

A new report presenting year 2000 trends on prescription drug spending, summarizing states options in designing their benefit, and reviewing several ways states are using their flexibility to curb the rate of growth of their Medicaid drug budgets.Background Paper